pharma · Weight management · Short Bowel Syndrome
Zealand Pharma
Zealand Pharma A/S
Zealand Pharma A/S is a pharma organization headquartered in EU. Primary therapeutic focus areas include Weight management, Short Bowel Syndrome, Children with congenital hyperinsulinism, Critically Ill, Mechanically Ven
Sydmarken 11, Søborg (Copenhagen), 2860, DK HQ
1998 Founded
596 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Sydmarken 11, Søborg (Copenhagen), 2860, DK
- Founded
- 1998
- Employees
- 596
- Programs
- 18
- Drugs
- 20
- Patents
- 0
Dasiglucagon 4 mg/ml
Phase 3 · small molecule · Children with congenital hyperinsulinism
Dasiglucagon 4 mg/ml for Children with congenital hyperinsulinism is a Phase 3 program (small_molecule) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).
Internal code ZP4207-17106
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zealand Pharma A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Children with congenital hyperinsulinism
- Status
- active
- Trials
- 1